How to buy SQZ Biotechnologies stock (SQZ Biotechnologies)

SQZ Biotechnologies is a biotechnology & medical research business based in the US. SQZ Biotechnologies shares (SQZ) are listed on the NYSE and all prices are listed in US Dollars. SQZ Biotechnologies employs 53 staff and has a trailing 12-month revenue of around $18.6 million.

Our top picks for where to buy Sqz Biotechnologies Co stock

Buy SQZ Biotechnologies stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

SQZ Biotechnologies stock price (NYSE: SQZ)

Use our graph to track the performance of SQZ stocks over time.

SQZ Biotechnologies shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$0.47
200-day moving average more info button	$1.09
Wall St. target price	$19.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-2.16

Is it a good time to buy SQZ Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

SQZ Biotechnologies financials

Revenue TTM	$18.6 million
Gross profit TTM	$-43,050,000
Return on assets TTM	-33.32%
Return on equity TTM	-104.93%
Profit margin	0%
Book value	$1.36
Market Capitalization more info button	$12.8 million

TTM: trailing 12 months

SQZ Biotechnologies share dividends

We're not expecting SQZ Biotechnologies to pay a dividend over the next 12 months.

You may also wish to consider:

• Bristol-Myers Squibb Company (BMY.US) (4.3% forward annual dividend yield)

Have SQZ Biotechnologies's shares ever split?

SQZ Biotechnologies's shares were split on a 1:10 basis on 6 July 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your SQZ Biotechnologies shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for SQZ Biotechnologies shares which in turn could have impacted SQZ Biotechnologies's share price.

SQZ Biotechnologies share price volatility

Over the last 12 months, SQZ Biotechnologies's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while SQZ Biotechnologies's is 2.707. This would suggest that SQZ Biotechnologies's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put SQZ Biotechnologies's beta into context you can compare it against those of similar companies.

• EXACT Sciences Corporation (EXAS.US): 1.272
• Bristol-Myers Squibb Company (BMY.US): 0.441
• Inovio Pharmaceuticals (INO.US): 0.833

SQZ Biotechnologies overview

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. .

Frequently asked questions

What percentage of SQZ Biotechnologies is owned by insiders or institutions?
Currently 3.123% of SQZ Biotechnologies shares are held by insiders and 66.581% by institutions. How many people work for SQZ Biotechnologies?
Latest data suggests 53 work at SQZ Biotechnologies. When does the fiscal year end for SQZ Biotechnologies?
SQZ Biotechnologies's fiscal year ends in December. Where is SQZ Biotechnologies based?
SQZ Biotechnologies's address is: 200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472 What is SQZ Biotechnologies's ISIN number?
SQZ Biotechnologies's international securities identification number is: US78472W1045